Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related ...

Preclinical results from St. Jude Children’s Research Hospital show that an RNA-targeted therapy can restore function in a ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the ...

Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...

Researchers found that adding a newly developed modified sugar, BNAP-AEO, to gapmer antisense oligonucleotides (ASOs) increased their affinity for target RNAs, thus significantly enhancing their ...

For the roughly one million Americans living with Parkinson’s disease, every approved treatment does the same thing: manage ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs ...

Active antisense oligonucleotides directed against the insulin-like growth factor type I receptor (IGF-IR/AS ODN) have shown potential as an antitumour agent in animal studies. In April Journal of ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...